Background Biosimilars have been introduced with the goal of competing with high-priced
biologic therapies, yet their adoption has been slower than expected and resulted in limited …

Background Biosimilars have the potential to increase patient access and significantly
reduce healthcare costs in the US. However, uptake in the US has been slower than …

Introduction Infliximab (IFX) biosimilars are available to treat inflammatory bowel disease
(IBD), offering cost reductions versus originator IFX in some jurisdictions. However, concerns …

Methods| This study was approved by the University of Southern California's institutional
review board. Consent was waived due to the use of deidentified existing data. We first …

Abstract Background and Objective Biosimilars represent an opportunity to realise savings
against the costs of innovative medicines. Despite efforts made by stakeholders, there are …

In response to a published national payer survey indicating striking needs for
multistakeholder initiatives to increase biosimilar adoption, a focus workgroup meeting …

Using Medicare claims, we documented US prescribing patterns for originator biologic
trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019 …

Among 196,766 commercially insured and Medicare Advantage patients who newly initiated
biologic drugs with available biosimilar versions, biosimilar initiation increased from 1 …

Nosocomial infections are a significant cause of morbidity, mortality, and increased
treatment costs in hospitals. This study aimed to analyze the factors determining the …

Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …